US Patent

US10112942 — Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors

Composition of Matter · Assigned to Array Biopharma Inc · Expires 2037-10-10 · 11y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a class of compounds that inhibit RET kinase and are useful in treating and preventing diseases associated with RET kinase.

USPTO Abstract

Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X 1 , X 2 , X 3 , X 4 , Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Drugs covered by this patent

Patent Metadata

Patent number
US10112942
Jurisdiction
US
Classification
Composition of Matter
Expires
2037-10-10
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Array Biopharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.